Antiepileptic Drugs in the Treatment of Psychiatric Diseases

  • Andres M. Kanner
  • Susan Palac
Conference paper


In the last two decades, antiepileptic drugs (AEDs) have been used for the management of psychiatric disorders. Their greatest use has been in the management of bipolar disorders, although more recent studies have demonstrated the efficacy of AEDs in anxiety disorders, unipolar depression, and the process of detoxifying patients from alcohol and cocaine. In this chapter, we briefly review the evidence in support of the use of AEDs in psychiatric disorders.


Bipolar Disorder Anxiety Disorder Panic Disorder Clin Psychiatry Manic Episode 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Dalby MA (1971) Antiepileptic and psychotropic effect of carbamazepine (Tegretoi) in the treatment of psychomotor epilepsy. Epilepsia 12:325–334PubMedCrossRefGoogle Scholar
  2. 2.
    Okuma T (1983) Therapeutic and prophylactic effects of carbamazepine in bipolar disorders. Psychiatr Clin N Am 6:157–174Google Scholar
  3. 3.
    Takezaki H, Hanaoka M (1971) The use of carbamazepine (Tegretol) in the control of manic-depressive psychosis and other manic-depressive states. Clin Psychiatry 13:173–183Google Scholar
  4. 4.
    Ballenger JC, Post RM (1980) Carbamazepine in manic-depressive illness: a new treatment. Am J Psychiatry 137:782–790PubMedGoogle Scholar
  5. 5.
    Okuma T, Kazutoyo I, Otsuki S, et al (1981) A preliminary double-blind study on the efficacy of carbamazepine in prophylaxis of manic-depressive illness. Psychopharmacology 73:95–96PubMedCrossRefGoogle Scholar
  6. 6.
    Post RM, Uhde TW, Ballenger JC, et al (1983) Prophylactic efficacy of carbamazepine in manic-depressive illness. Am J Psychiatry 140:1602–1604PubMedGoogle Scholar
  7. 7.
    Placidi GF, Lenzi A, Lazzerini F, et al (1986) The comparative efficacy and safety of carbamazepine versus lithium: a randomized, double-blind 3-year trial in 83 patients. J Clin Psychiatry 47:490–494PubMedGoogle Scholar
  8. 8.
    Watkins SE, Callender K, Thomas DR, et al (1987) The effect of carbamazepine and lithium on remission from affective illness. Br J Psychiatry 150:180–182PubMedCrossRefGoogle Scholar
  9. 9.
    Lusznat RM, Murphy DP, Nunn CM (1988) Carbamazepine vs.lithium in the treatment and prophylaxis of mania. Br J Psychiatry 153:198–204PubMedCrossRefGoogle Scholar
  10. 10.
    Small JG, Klapper MH, Milstein V, et al (1991) Carbamazepine compared with lithium in the treatment of mania. Arch Gen Psychiatry 48:915–921PubMedCrossRefGoogle Scholar
  11. 11.
    Coxhead N, Silverstone T, Cookstone J (1992) Carbamazepine versus lithium in the prophylaxis of bipolar affective disorder. Acta Psychiatr Scand 85:114–118PubMedCrossRefGoogle Scholar
  12. 12.
    Simhandl C, Denk E, Thau K (1993) The comparative efficacy of carbamazepine low and high serum levels and lithium carbonate in the prophylaxis of affective disorders. J Affect Disord 28:221–231PubMedCrossRefGoogle Scholar
  13. 13.
    Denicoff KD, Smith-Jackson EE, Disney ER, et al (1997) Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disease. J Clin Psychiatry 58:470–478PubMedCrossRefGoogle Scholar
  14. 14.
    Greil W, Ludwig-Mayerhofer W, Erazo N, et al (1997) Lithium versus carbamazepine in the maintenance treatment of bipolar disorders-a randomized study. J Affect Disord 43:151–161PubMedCrossRefGoogle Scholar
  15. 15.
    Kishimoto A, Ogura C, Hazama H, et al (1983) Long-term prophylactic effects of carbamazepine in affective disorder. Br J Psychiatry 143:327–331PubMedCrossRefGoogle Scholar
  16. 16.
    Nolen WA (1983) Carbamazepine: a possible adjunct or alternative to lithium in bipolar disorders. Acta Psychiatr Scand 67:218–225PubMedCrossRefGoogle Scholar
  17. 17.
    Folks DG, King LD, Dowdy SB, et al (1982) Carbamazepine treatment of selected affectively disordered inpatients. Am J Psychiatry 139: 115–117PubMedGoogle Scholar
  18. 18.
    Lipinski JF, Pope HA (1982) Possible synergistic action between carbamazepine and lithium carbonate in the treatment of three acutely manic patients. Am J Psychiatry 139:948–949PubMedGoogle Scholar
  19. 19.
    Keisling R (1983) Carbamazepine and lithium carbonate in the treatment of refractory affective disorders. Arch Gen Psychiatry 40:223PubMedCrossRefGoogle Scholar
  20. 20.
    Warren JA, Crismon ML (1982) Carbamazepine in bipolar disorder-mixed. Clin Pharmacoll:266–268Google Scholar
  21. 21.
    Fritze J, Beneke M, Lanczik M, et al (1994) Carbamazepine as adjunct or alternative to lithium in the prophylaxis of recurrent affective disorders. Pharmacopsychiatry 27:181–185PubMedCrossRefGoogle Scholar
  22. 22.
    Calabrese JR, Delucchi GA (1990) Spectrum of efficacy of valproate in 55 patients with rapid-cycling bipolar disorder. Am J Psychiatry 147:431–434PubMedGoogle Scholar
  23. 23.
    Deltito JA Levitan J, Damore J, et al (1998) Naturalistic experience with the use of divalproex sodium on an inpatient unit for adolescent psychiatric patients. Acta Psychiatr Scand 97:236–240PubMedCrossRefGoogle Scholar
  24. 24.
    Keck PE, McElroy SL, Tugrul KC, et al (1993) Valproate oral loading in the treatment of acute mania. J Clin Psychiatry 54:305–308PubMedGoogle Scholar
  25. 25.
    McElroy SL, Keck PE, Stanton SP, et al (1996) A randomized comparison of divalproex oral loading versus haloperidol in the initial treatment of acute psychotic mania. J Clin Psychiatry 57:142–146PubMedGoogle Scholar
  26. 26.
    Papatheodorou G, Kutcher SP, Katic M, et al (1995) The efficacy and safety of divalproex sodium in the treatment of acute mania in adolescents and young adults: an open clinical trial. J Clin Psychopharmacol 15:110–116PubMedCrossRefGoogle Scholar
  27. 27.
    Pope HG, McElroy SL, Keck PE, et al (1991) Valproate in the treatment of acute mania. Arch Gen Psychiatry 48:62–68PubMedCrossRefGoogle Scholar
  28. 28.
    Bowden CL, Brugger AM, Swann AC, et al (1994) Efficacy of divalproex vs.lithium and placebo in the treatment of mania. JAMA 271:918–924PubMedCrossRefGoogle Scholar
  29. 29.
    Freeman TW, Clothier JL, Pazzaglia P, et al (1992) A double-blind comparison of valproate and lithium in the treatment of acute mania. Am J Psychiatry 149: 108–111PubMedGoogle Scholar
  30. 30.
    Emrich HM, Dose M, Vonzerssen D (1985) The use of sodium valproate, carbamazepine, and oxcarbazepine in patients with affective disorders. J Affect Disord 8:243–250PubMedCrossRefGoogle Scholar
  31. 31.
    Herbert P.B., Nelson JC (2000) Parenteral valproate for control of acute mania (letter). Am J Psychiatry 157:1023–1024PubMedCrossRefGoogle Scholar
  32. 32.
    Norton JW, Quarles E (2000) Intravenous valproate in neuropsychiatry. Pharmacotherapy 20:88–92PubMedCrossRefGoogle Scholar
  33. 33.
    Solomon DA, Ryan CE, Keitner GI, et al (1997) A pilot study of lithium carbonate plus divalproex sodium for the continuation and maintenance treatment of patients with bipolar I disorder. J Clin Psychiatry 58:95–99PubMedCrossRefGoogle Scholar
  34. 34.
    Bowden CL, Calabrese JR, McElroy SL, et al (2000) A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Arch Gen Psychiatry 57:481–489PubMedCrossRefGoogle Scholar
  35. 35.
    Ryback RS, Brodsky L, Munasifi F (1997) Gabapentin in bipolar disorder (letter). J Neuropsychiat Clin Neurosci 9:301Google Scholar
  36. 36.
    Stanton SP, Keck PE Jr, McElroy SL (1997) Treatment of acute mania with gabapentin (letter). Am J Psychiatry 154:287PubMedGoogle Scholar
  37. 37.
    Bennett J, Goldman W, Suppes T (1997) Gabapentin for treatment of bipolar and schizo affective disorders (letter). J Clin Psychopharmacol 17:141–142PubMedCrossRefGoogle Scholar
  38. 38.
    Schaffer CB, Schaffer LC (1999) Open maintenance treatment of bipolar disorder spectrum patients who responded to gabapentin augmentation in the acute phase of treatment. J Affect Disord 55:237–240PubMedCrossRefGoogle Scholar
  39. 39.
    Ghaemi SN, Katzow JJ, Desai SP, et al (1998) Gabapentin treatment of mood disorders: a preliminary study. J Clin Psychiatry 59:426–429PubMedCrossRefGoogle Scholar
  40. 40.
    Young LT, Robb JC, Hasey GM, et al (1999) Gabapentin as an adjunctive treatment in bipolar disorder. J Affect Disord 55:73–77PubMedCrossRefGoogle Scholar
  41. 41.
    Sporn J, Sachs G (1997) The anticonvulsant lamotrigine in treatment-resistant manic-depressive illness. J Clin Psychopharmacol 17:185–189PubMedCrossRefGoogle Scholar
  42. 42.
    Kusumakar V, Yatham LN (1997) An open study of lamotrigine in refractory bipolar depression. Psychiatry Res 72: 145–148PubMedCrossRefGoogle Scholar
  43. 43.
    Fatemi SH, Rapport DJ, Calabrese JR, et al (1997) Lamotrigine in rapid-cycling bipolar disorder. J Clin Psychiatry 58:522–527PubMedCrossRefGoogle Scholar
  44. 44.
    Calabrese JR, Bowden CL, Sachs GS, et al (1999) A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. J Clin Psychiatry 60:79–88PubMedCrossRefGoogle Scholar
  45. 45.
    Marcotte D (1998) Use of topiramate: a new anti-epileptic as a mood stabilizer. J Affect Disord 50:245–251Google Scholar
  46. 46.
    Post RM, Uhde TW, Roy-Byrne PP, et al (1986) Antidepressant effects of carbamazepine. Am J Psychiatry 143:29–34PubMedGoogle Scholar
  47. 47.
    Kemp LI (1992) Sodium valproate as an antidepressant. Br J Psychiatry 160:121–123PubMedCrossRefGoogle Scholar
  48. 48.
    Pies R, Adler DA, Ehrenberg BL (1989) Sleep disorders and depression with atypical features: response to valproate. J Clin Psychopharmacol 9:352–357PubMedCrossRefGoogle Scholar
  49. 49.
    Davis LL, Kabel D, Patel D, et al (1996) Valproate as an antidepressant in major depressive disorder. Psychopharmacol Bull 32:647–652PubMedGoogle Scholar
  50. 50.
    Primeau F, Fontaine R, Beaclair L (1990) Valproic acid and panic disorder. Can J Psychiatry 35:248–250PubMedGoogle Scholar
  51. 51.
    Woodman CL, Noyes R (1994) Panic disorder: treatment with valproate. J Clin Psychiatry 55:134–136PubMedGoogle Scholar
  52. 52.
    Lum M, Fontaine R, Elie R, et al (1991) Probable interaction of sodium divalproex with benzodiazepines. Prog Neuropsychopharmacol Biol Psychiatry 15:269–273PubMedCrossRefGoogle Scholar
  53. 53.
    Chouinard G, Beauclair L, Belanger MC (1998) Gabapentin: long-term antianxiety and hypnotic effects in psychiatric patients with comorbid anxiety-related disorders. Can J Psychiatry 43:305PubMedGoogle Scholar
  54. 54.
    Pollack MG, Matthews J, Scott EL (1998) Gabapentin as a potential treatment for anxiety disorders. Am J Psychiatry 155:992–993PubMedGoogle Scholar
  55. 55.
    Pande AC, Davidson JR, Jefferson JW, et al (1999) Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol 19:341–348PubMedCrossRefGoogle Scholar
  56. 56.
    Uhde TW, Stein MB, Post RM (1988) Lack of efficacy of carbamazepine in the treatment of panic disorder. Am J Psychiatry 145: 1104–1109PubMedGoogle Scholar
  57. 57.
    Lambie DG, Johnson RH, Vijayasenan M.E., et al (1980) Sodium valproate in the treatment of the alcohol withdrawal syndrome. Aust N Z J Psychiatry 14:213–215PubMedCrossRefGoogle Scholar
  58. 58.
    Rosenthal RN, Perkel C, Singh P, et al (1998) A pilot open randomized trial of valproate and phenobarbital in the treatment of acute alcohol withdrawal. Am J Addict 7: 189–197PubMedGoogle Scholar
  59. 59.
    Hammer BA, Brady KT (1996) Valproate treatment of alcohol withdrawal and mania (letter). Am J Psychiatry 153:1232PubMedGoogle Scholar
  60. 60.
    Rickels K, Schweizer E, Garcia Espana F, et al (1999) Trazadone and valproate in patients discontinuing long-term benzodiazepine therapy: effects of withdrawal symptoms and taper outcome. Psychopharmacology 141:1–5PubMedCrossRefGoogle Scholar
  61. 61.
    Ries RK, Roy-Byrne PP, Ward N.G., et al (1989) Carbamazepine treatment for benzodiazepine withdrawal. Am J Psychiatry 146:536–537PubMedGoogle Scholar
  62. 62.
    Montoya ID, Levin FR, Fudala PJ, et al (1995) Double-blind comparison of carbamazepine and placebo for treatment of cocaine dependence. Drug Alcohol Dependence 38:213–219CrossRefGoogle Scholar
  63. 63.
    Cornish JW, Maany I, Fudala PJ, et al (1995) Carbamazepine treatment for cocaine dependence. Drug Alcohol Dependence 38:221–227CrossRefGoogle Scholar
  64. 64.
    Kranzler HR, Bauer LO, Hersh D (1995) Carbamazepine treatment of cocaine dependence: a placebo-controlled trial. Drug Alcohol Dependence 38:203–211CrossRefGoogle Scholar
  65. 65.
    Donovan SJ, Stewart JW, Nunes EV, et al (2000) Divalproex treatment for youth with explosive temper and mood lability: a double-blind, placebo-controlled crossover design. Am J Psychiatry 157:818–820PubMedCrossRefGoogle Scholar
  66. 66.
    Kavoussi RJ, Coccaro EF (1998) Divalproex sodium for impulsive aggressive behavior in patients with personality disorder. J Clin Psychiatry 59:676–680PubMedCrossRefGoogle Scholar
  67. 67.
    Daly KA, Fatemi SH (1999) Lamotrigine and impulse behaviour (letter). Can J Psychiatry 44:395–396PubMedGoogle Scholar

Copyright information

© Springer Japan 2001

Authors and Affiliations

  • Andres M. Kanner
    • 1
  • Susan Palac
    • 1
  1. 1.Department of Neurological SciencesRush-Presbyterian-St. Luke’s Medical CenterChicagoUSA

Personalised recommendations